A new system that contains a gene-modulating therapy attached to an antibody that enables crossing into the nervous system improved survival outcomes in a mouse model of severe spinal muscular atrophy (SMA), a new study reports. The study, “Antibody-oligonucleotide conjugate achieves central nervous system delivery in…
Children with spinal muscular atrophy (SMA) who have lower levels of an inflammatory protein called interleukin-8 (IL-8) in the fluid surrounding the brain and spinal cord tend to respond better to treatment with Spinraza (nusinersen), a new study suggests. The findings indicate that IL-8 is a better predictor of…
After two years of treatment with Evrysdi (risdiplam), most babies with spinal muscular atrophy (SMA) type 1 in the FIREFISH clinical trial are still alive without a need for permanent ventilation, and many of the youngsters are showing continual improvements in motor development. The results were published in …
Continued treatment with apitegromab, designed to strengthen muscles, led to stabilization or improvement in measures of fatigue and life quality for children and young adults with types 2 and 3Â spinal muscular atrophy (SMA), according to new data from the TOPAZ clinical trial. According to apitegromab’s developer…
Children with spinal muscular atrophy (SMA) switching from Spinraza (nusinersen) to Evrysdi (risdiplam) are generally optimistic about the switch as are their caregivers, according to a new study. The report, “How children and caregivers viewed the change from nusinersen to risdiplam for treating spinal…
Levels of an immune protein called CHIT1 change over time in children with spinal muscular atrophy (SMA) who undergo treatment with Spinraza (nusinersen), a small study reports. The findings thus suggest that the protein’s levels — in the cerebrospinal fluid or CSF, the liquid surrounding the brain and…
Treatment with Evrysdi (risdiplam) increased levels of SMN protein and stabilized motor function in a Phase 2 clinical trial that enrolled spinal muscular atrophy (SMA) patients who had previously been on other therapies, two-year data show. “These important data demonstrate the safety and efficacy of Evrysdi in a…
The gene therapy Zolgensma (onasemnogene abeparvovec-xioi), approved in the U.S. for very young children with spinal muscular atrophy (SMA), potentially could work for adults with the rare genetic disorder, a new study suggests. The study reports that few adults with SMA were found to have antibodies against the…
Doctors need to be well-educated about options in the evolving treatment landscape to help patients with spinal muscular atrophy (SMA) make informed decisions, say neurologists in a panel discussion. The panel of four neurologists with experience in treating SMA patients was convened by Biogen, which markets…
Note: This story was updated Sept. 19, 2022, to correct that 78.9% of the survey respondents would choose an ASO or a small molecule therapy, such as Evrysdi (risdiplam), if they were approved therapies. Many members of the spinal muscular atrophy (SMA) community are interested in the…
